Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing lorundrostat, a proprietary oral aldosterone synthase inhibitor, to treat uncontrolled and resistant hypertension and related cardiorenal disorders (including CKD and OSA). The company focuses on targeted therapies for diseases driven by dysregulated aldosterone and is advancing late-stage clinical programs and regulatory filings to bring this treatment to patients.